Sensocure
1 known investors
Sensocure develops IscAlert, a biomedical sensor that measures tissue partial pressure of carbon dioxide (pCO₂) to indicate perfusion status and detect the early, reversible stages of ischemia before irreversible tissue injury occurs. The device is CE-marked under the EU Medical Device Regulation and the company is ISO 13485 certified.
Also known as Sensocure AS · SENSOCURE AS
Investors · 1
Company profile
researched Aug 2026Sensocure AS is a Norwegian medical technology company headquartered in Horten, Norway, that develops and manufactures biomedical sensors for healthcare, with a focus on monitoring tissue perfusion and postoperative monitoring of organs. Its principal product, IscAlert, is a sensor system that continuously measures the partial pressure of carbon dioxide (pCO2) in tissue local to sensor placement in order to indicate the perfusion status of muscle, subcutaneous tissue, connective tissue or mucosal membranes. Because tissue pCO2 rises significantly during the early and reversible stages of ischemia, continuous monitoring is intended to identify the onset of ischemic events before irreversible injury such as muscle atrophy, loss of skin integrity, soft-tissue necrosis or impaired wound healing occurs.
IscAlert is a single-use, surgically invasive sensor intended for short-term use of up to 14 days. The sensor is less than 1 mm in diameter, sterile and biocompatible, and is placed using a dedicated IscAlert Introducer. The company states that clinical trials have shown no serious side effects. Application scenarios described include acute ischemia in replantation and reconstructive surgery, compartment syndrome, and systemic conditions altering organ perfusion. A second system, CriticAlert, is under development as a sensor system aimed at early warning of circulatory and respiratory problems, targeted at patients with hypoxia or hypercapnia, COPD, pneumonia, post-operative respiratory complications and intensive care respiratory surveillance.
Sensocure AS is ISO 13485 certified and IscAlert is CE marked in compliance with the EU Medical Device Regulation (MDR) 2017/745. The company states it is preparing a 510(k) premarket submission to obtain FDA clearance for IscAlert.
Founding story
Sensocure was founded by Tor Inge Tønnessen, Professor of Anesthesiology and Intensive Care at Oslo University Hospital, who describes a medical need for real-time measurement of whether tissues receive sufficient blood supply, insufficient supply being a common cause of illness, death and post-operative complications.
Business model
The company develops and manufactures biomedical sensor devices for healthcare providers, centred on the single-use IscAlert sensor and its introducer, supported by regulatory certification (ISO 13485, EU MDR CE mark) required for clinical sale.
Traction
The company completed its first clinical trial in June 2022, obtained ISO 13485 certification and a CE mark for IscAlert under EU MDR 2017/745, and is preparing a 510(k) submission for FDA clearance. It is part of the EIC Fund portfolio and was selected for a healthcare innovation accelerator bridging the Norwegian and U.S. markets.
Latest developments
In January 2025 the company announced that the European Innovation Council Fund invested NOK 12 million as part of a NOK 24 million total equity round including existing and new shareholders, intended to move the company into its commercial phase. The company also reported being selected for a healthcare innovation accelerator bridging the Norwegian and U.S. markets, and coverage in the newspaper Gjengangeren.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Sensocure describes IscAlert as the world's first pCO2 sensor designed for the earliest possible detection of ischemia and positions it against existing detection solutions that it says identify organ injury too late. The European Innovation Council characterises the company as developing a breakthrough biomedical sensor for continuous real-time detection of ischemia in the medical technologies sector.
Technology
IscAlert measures the partial pressure of carbon dioxide in tissue as a marker of metabolic distress arising from compromised circulation and oxygen delivery. The company describes the solution as patented, sensitive to small early pCO2 variations, and capable of continuous real-time readings, in contrast to detection methods that identify organ injury late. The sensor is under 1 mm in diameter, sterile and biocompatible, and is designed for short-term (up to 14 days) invasive placement. The CriticAlert system under development extends the sensing approach to circulatory and respiratory monitoring.
Go-to-market
Funding from the January 2025 equity round is stated to be used to accelerate commercialization and market access in Norway and Europe for IscAlert, alongside pursuit of U.S. FDA clearance.
Surgeons, hospitals and healthcare organisations monitoring patients at risk of ischemia — including replantation and reconstructive surgery, compartment syndrome and post-operative monitoring — and, for the CriticAlert system in development, respiratory and intensive care patient populations.
Geography
Headquartered in Horten, Norway; stated commercialization and market access focus on Norway and Europe, with a U.S. regulatory pathway being pursued via FDA 510(k).
Risks & controversies
IscAlert is a surgically invasive device dependent on regulatory approvals; U.S. market entry remains subject to a pending 510(k) submission to the FDA, and the CriticAlert system is still in development.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsThe European Innovation Council Fund invested 12 million NOK in Sensocure; total equity investment in the round was 24 million NOK from existing and new shareholders, intended to accelerate commercialization and market access in Norway and Europe for IscAlert.
IscAlert is CE marked in compliance with the Medical Device Regulation (EU) 2017/745; the company also states it is ISO 13485 certified and is preparing a 510(k) submission for FDA clearance.
Sensocure completed its first clinical trial for IscAlert in June 2022.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Sensocuresensocure.no · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Sensocure do?
- Norwegian medtech company making IscAlert, a tissue pCO2 sensor for real-time, early detection of ischemia.
- Who are Sensocure's investors?
- Sensocure's investors include Skagerak Capital.